Adaptimmune Therapeutics Plc
(NASDAQ : ADAP)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -4.90%58.570.0%$906.01m
AMGNAmgen, Inc. 1.22%258.241.3%$750.82m
GILDGilead Sciences, Inc. 0.38%76.351.0%$724.94m
REGNRegeneron Pharmaceuticals, Inc. 2.18%622.452.5%$659.43m
NVAXNovavax, Inc. 2.43%81.64102.0%$580.82m
BIIBBiogen, Inc. 0.13%265.121.6%$559.05m
VRTXVertex Pharmaceuticals, Inc. 1.68%291.101.9%$527.74m
ILMNIllumina, Inc. 1.24%373.103.5%$308.62m
ALXNAlexion Pharmaceuticals, Inc. -0.08%112.302.0%$228.46m
BMRNBioMarin Pharmaceutical, Inc. 0.75%126.784.3%$214.78m
SGENSeattle Genetics, Inc. 0.90%169.036.1%$202.30m
SRNESorrento Therapeutics, Inc. -1.15%6.851.8%$184.40m
SRPTSarepta Therapeutics, Inc. -1.77%162.7513.9%$167.23m
INCYIncyte Corp. 3.72%106.472.5%$163.35m
IMMUImmunomedics, Inc. 1.71%37.5411.0%$159.56m

Company Profile

Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.